NCT03920215View on ClinicalTrials.gov

Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

August 15, 2018

Primary Completion Date

September 20, 2019

Study Completion Date

September 20, 2019

Conditions
Long Term Follow up Dry Eye Disease
Interventions
DRUG

OC-01 Low Dose, 0.12 mg/mL

OC-01 (varenicline) nasal spray

DRUG

OC-01 Mid Dose, 0.6 mg/mL

OC-01 (varenicline) nasal spray

DRUG

OC-01 High Dose, 1.2 mg/mL

OC-01 (varenicline) nasal spray

DRUG

Placebo (vehicle) nasal spray

Placebo (vehicle) nasal spray

Trial Locations (3)

46290

Indianapolis, Indianapolis

92663

Newport Beach, Newport Beach

01810

Andover, Andover

Sponsors
All Listed Sponsors
lead

Oyster Point Pharma, Inc.

INDUSTRY

NCT03920215 - Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease | Biotech Hunter | Biotech Hunter